Successful Treatment of a Case with Rhino-Orbital-Cerebral Mucormycosis by the Combination of Neurosurgical Intervention and the Sequential Use of Amphotericin B and Posaconazole

Young Kyung Yoon, M.D.,1 Min Ja Kim, M.D.,1 Yong Gu Chung, M.D.,2 Il Young Shin, M.D., Ph.D.2
Division of Infectious Diseases,1 Departments of Internal Medicine, Neurosurgery,2 College of Medicine, Korea University, Korea

INTRODUCTION

Mucormycosis is uncommon but has become more prevalent due to the growing number of patients with metabolic or immunologic imbalances.16 It remains as a potentially lethal fungal infection, even though antifungal therapy and aggressive surgical intervention are currently available.3 Rhinocerebral mucormycosis is the most common clinical form, accounting for about 50% of the reported cases, and the most fatal clinical category, compared to pulmonary, cutaneous, gastrointestinal and disseminated mucormycosis.19 It is further divided into three subtypes: rhinomaxillary, rhinoorbital and rhino-orbital-cerebral (ROC).19 Approximately 70% of rhinocerebral cases were found in diabetic patients with ketoacidosis.12

The survival rate is 82% for patients with isolated rhinomaxillary mucormycosis, whereas the prognosis is markedly poor in cases of cerebral involvement, with a survival rate of 38-50%, despite aggressive surgery, antifungal therapy and reversal of underlying predisposing factors.16,19,23 Surgical intervention has been relegated to an adjunctive role in the treatment of these patients because of deformed function and disfiguration of appearance from radical surgery. Importantly, angioinvasion, thrombosis and tissue necrosis of the disease might result in the poor penetration of antifungal agents to the site of the infection. In addition, amphotericin B penetrates poorly into the blood-brain barrier, making it difficult to achieve effective fungicidal levels in cerebral lesions. Therefore, surgical intervention should be considered in the treatment of mucormycosis with necrotic tissues and cerebral lesions.

Here, we describe a patient with ROC mucormycosis who was successfully treated by the strict control of blood sugar levels, sequential antifungal therapy of amphotericin B and posaconazole, as well as aggressive neurosurgical intervention.
CASE REPORT

A 46-year-old female presented with progressive peri-orbital swelling and headache for a week. She had received endoscopic sinus surgery and antibiotic treatment due to the right-sided sinusitis at a local ENT clinic 2 months prior to admission. An ophthalmologic examination on admission showed tenderness and erythema of the right upper eyelid and lacrimal sac, but no proptosis was visible. Her visual acuity was 20/20 OD and a fundoscopic examination revealed normal results. An endoscopic examination of her nasal cavities revealed necrotic materials with thick purulent discharge in the right side. Other physical and neurological findings did not reveal any out of the ordinary results. The laboratory values included a white blood cell count of 3,020 cells/microliter, with 66.5% neutrophils, hemoglobin of 9.8 g/dL, hematocrit of 28.6%, platelet count of 94,000 cells/microliter, a blood urea nitrogen concentration of 15.7 mg/dL, a serum creatinine of 0.9 mg/dL and C-reactive protein of 3.0 mg/L. Her random and fasting blood glucose levels were 213 and 138 mg/dL, respectively. HbA1c was 6.4%. She had no known history of diabetes before she presented with ROC mucormycosis.

We retrospectively reviewed the findings of a prior nasal biopsy from the local ENT clinic, which revealed copious fungal hyphae, suggestive of mucormycosis. Treatment with amphotericin B was immediately started. Magnetic resonance imaging (MRI) demonstrated high signals on the soft tissues of the right-sided maxillary and ethmoid sinuses, on the periorbital fat with local bony erosions in the infratemporal fossa and pericranial abscess in the frontotemporal region (Fig. 1A).

Because the patient refused to have aggressive debridement of her facial and peri-orbital lesions, she was medically treated with amphotericin B, up to 4,525 mg for the initial 30 days, along with the strict control of her blood glucose levels. When the follow-up MRI revealed pericranial abscess and osteomyelitis in the frontotemporal region, in spite of moderate improvement of her facial and periorbital lesions, she then agreed with the doctor's decision to undergo neurosurgical intervention. A frontal craniectomy showed osteomyelitis with extensive bone invasion and pericranial abscess in the frontotemporal region. Extensive bony debridement, removal of the involved dura and surrounding necrotic tissues and drainage of the pericranial abscess were performed. We used lyophilized dura (Lyodura, B. Braun Melsungen, Germany) and artificial bone grafts (Biobone, Johnson & Johnson, Tokyo, Japan) for the cranioplasty. A pathologic examination of her necrotic tissues revealed inflammation with neutrophils, lymphocytes, scattered multinucleated giant cells, and wide, nonseptate, right-angled branched hyphae on Hematoxylin and Eosin stain and the Gomori methenamine silver stain (Fig. 2). Hyphae were invading the cortical bone and skin of the frontal area. Fungal cultures of the removed tissue were negative. Amphotericin B was administered, up to a total of 5,225 mg, used for 31 days after the neurosurgery. She had no adverse effects related to amphotericin B. The follow-up MRI revealed the disappearance of the pericranial abscess by surgical removal and a decrease in the enhanced periorbital lesions, but residual lesions were present (Fig. 1B). Laboratory findings on the follow-up were normal except...
for C-reactive protein of 3.5 mg/L. She was discharged from the hospital with a prescription of posaconazole (400mg twice daily) as an oral step-down therapy. The posaconazole was prescribed for a total of 26 days, when her symptoms and signs no longer existed and the C-reactive protein decreased to 0.32 mg/L. At the time of completion of her treatment, MRI showed more improvement (Fig. 1C). The patient has been disease free until the time of a 15 month follow-up from the completion of the treatment.

**DISCUSSION**

Rhinocerebral mucormycosis is easy to mistake for common bacterial sinusitis on initial diagnosis. A delay in diagnosis and appropriate therapy might be associated with high mortality. A multiplicity of underlying diseases can predispose to mucormycosis. As diabetes mellitus is the most common risk factor, mucormycosis should be suspected in the patients with diabetes mellitus who are diagnosed with sinusitis. In our case, fungal sinusitis progressed to the ROC mucormycosis due to delayed diagnosis and treatment. Similarly, previous reported cases in the Korean literature mostly involved patients having diabetes and were initially mis-diagnosed as having acute sinusitis.

In the past decade, the aggressive surgical debridement of the lesions was considered as the treatment of choice for the ROC mucormycosis. Moreover, orbital exenteration was often indicated due to rapid extension into the orbits. With the advent of new therapeutic regimens, however, the treatment strategy now should include rapid diagnosis, reversal of underlying medical conditions, systemic use of antifungal agents and appropriate surgical debridement only as needed.

In the beginning of the treatment, our patient refused to have surgical debridement of her extensive facial and forehead lesions, because of the potential cosmetic problems and possible deformed functions of the face. But, her cerebral lesions showed no improvement with the medical therapy of amphotericin B and strict glucose control. Without the neurosurgical intervention, we think, it would have been far less likely for her to recover from the ROC mucormycosis.

Amphotericin B has been the first-line antifungal agent for rhinocerebral mucormycosis. The majority of the cases reported in the Korean literature were treated with amphotericin B. In the meanwhile, it must be taken in account that amphotericin B does not readily penetrate the blood-brain barrier and might be ineffective in cerebral mucormycosis. Because there are no reliable anti-fungal agents, surgical debridement combined with antifungal therapy is inevitable in the treatment of cerebral mucormycosis. Although the extent and timing of surgical debridement necessary to maximize the outcomes of mucormycosis has never been defined, a recent study supports the concept of an “aggressive-conservative” approach, that uninvolved tissues spared from debridement when possible.

Amphotericin B is limited in use by its renal and systemic toxic effects. New antifungal agents and a combination of existing agents in the treatment of mucormycosis have been reviewed recently. Posaconazole is a reasonable salvage option for patients with mucormycosis refractory to or intolerant to polyene therapy. The available data are insufficient to support a significant role of primary treatment for mucormycosis, however, posaconazole is an option for the oral step-down therapy for patients who have responded to amphotericin B. The drug is also beneficial in treatment and prevention of any relapse of central nervous system mucormycosis. Therefore, posaconazole might promise effective treatment to the ROC mucormycosis, even though more clinical experiences and clinical trial studies are needed.

Fig. 2. Microscopic finding. Wide unseptate hyphae with obtuse or right angle branching (H & E stain, original magnification × 400) (A), (Gomori-methanamine silver stain, × 400) (B).
CONCLUSION

The authors report a case of cured rhino-orbital-cerebral mucormycosis complicated with osteomyelitis and pericranial abscess. This study gives support to the essential role that neurosurgical intervention as well as the potential advantage of posaconazole as an oral step-down therapy should play in the treatment of rhino-orbital-cerebral mucormycosis.

Acknowledgements

The authors wish to thank Prof. Nam Joon Lee, the Department of Radiology, Korea Univ. Hospital for his valuable assistance during this work. Also, we would like to thank Prof. Chul Hwan Kim and Dr. Jeong Hyeon Lee, the Department of Pathology, Korea Univ. Hospital for their helpful pathological review.

References

1. Bhansali A, Bhadada S, Sharma A, Suresh V, Gupta A, Singh P, et al.: Presentation and outcome of rhino-orbital-cerebral mucormycosis in patients with diabetes. Postgrad Med J 80: 670-674, 2004
2. Chakrabarti A, Das A, Mandal J, Shivaparaksh MR, George VK, Tarai B, et al.: The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med Mycol 44: 335-342, 2006
3. Chakrabarti A, Das A, Sharma A, Panda N, Das S, Gupta KL, et al.: Ten years’ experience in zygomycosis at a tertiary care centre in India. J Infect 42: 261-266, 2001
4. Choi HY, Lew JM: Rhinocerebral mucormycosis combined with brain abscess. J Korean Soc Plast Reconstr Surg 16: 363-371, 1989
5. deShazo RD, Chapin K, Swain RE: Fungal sinusitis. N Engl J Med 337: 254-259, 1997
6. Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA: Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphoterica B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 41: 3623-3626, 2003
7. Han SR, Choi CY, Joo M, Whang CJ: Isolated cerebral mucormycosis. J Korean Neurosurg Soc 42: 400-402, 2007
8. Jeong H, Kang PJ, Lee JY, Cha KS, Lee ID, Son DH, et al.: A case of rhinocerebral mucormycosis associated with diabetes mellitus. Korean J Med 39: 715-720, 1990
9. Kim HJ, Choung YH, Cho MJ, Baik SS: Clinical analysis of eight cases of mucormycosis. J Clin Otolaryngol 15: 134-138, 2004
10. Lee CH, Jinn TH, Choi HY, Kim JY: Two cases of rhinocerebral mucormycosis. Korean J Otorhinolaryngol-Head Neck Surg 32: 139-144, 1989
11. Marom T, Watad W, Dan M, Roth Y: Posaconazole for bone-invading rhinomaxillary mucormycosis. Otolaryngol Head Neck Surg 140: 610-611, 2009
12. McNulty JS: Rhinocerebral mucormycosis: predisposing factors. Laryngoscope 92: 1140-1143, 1982
13. Peterson KL, Wang M, Canalis RF, Abemayer E: Rhinocerebral mucormycosis: evolution of the disease and treatment options. Laryngoscope 107: 855-862, 1997
14. Reed C, Bryant R, Ibrahim AS, Edwards J Jr, Filler SG, Goldberg R, et al.: Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 47: 364-371, 2008
15. Rickerts V, Atta J, Herrmann S, Jacob V, Lambrichts E, Bialek R, et al.: Successful treatment of disseminated mucormycosis with a combination of liposomal amphotericin B and posaconazole in a patient with acute myeloid leukaemia. Mycoses 49 Suppl 1: 27-30, 2006
16. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schauffele RL, et al.: Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 41: 634-653, 2005
17. Rogers TR: Treatment of zygomycosis: current and new options. J Antimicrob Chemother 61 Suppl 1: i35-i40, 2008
18. Scully EP, Baden LR, Katz JT: Fungal brain infections. Curr Opin Neurol 21: 347-352, 2008
19. Spellberg B, Edwards J Jr, Ibrahim A: Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 18: 556-560, 2005
20. Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J Jr, Ibrahim AS: Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis 48: 1743-1751, 2009
21. Tarani L, Costantino F, Notheis G, Wintergerst U, Venditti M, Di Biasi C, et al.: Long-term posaconazole treatment and follow-up of rhino-orbital-cerebral mucormycosis in a diabetic girl. Pediatr Diabetes 10: 289-293, 2009
22. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP: Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 42: e61-e65, 2006
23. Yehai RA, Bullock JD, Aziz AA, Markert RJ: Survival factors in rhino-orbital-cerebral mucormycosis. Surv Ophthalmol 39: 3-22, 1994